Format
Sort by
Items per page

Send to

Choose Destination

Links from Protein

Items: 1 to 20 of 22

1.

The Fe-heme structure of met-indoleamine 2,3-dioxygenase-2 determined by X-ray absorption fine structure.

Aitken JB, Austin CJ, Hunt NH, Ball HJ, Lay PA.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):25-9. doi: 10.1016/j.bbrc.2014.05.054. Epub 2014 May 22.

PMID:
24858687
2.

Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.

Fatokun AA, Hunt NH, Ball HJ.

Amino Acids. 2013 Dec;45(6):1319-29. doi: 10.1007/s00726-013-1602-1. Epub 2013 Oct 9. Review.

PMID:
24105077
3.

Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten Pt, Andersen MH.

Cancer Res. 2011 Mar 15;71(6):2038-44. doi: 10.1158/0008-5472.CAN-10-3403.

4.

Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation.

Cetindere T, Nambiar S, Santourlidis S, Essmann F, Hassan M.

Cell Signal. 2010 Feb;22(2):197-211. doi: 10.1016/j.cellsig.2009.09.013. Epub 2009 Sep 30. Erratum in: Cell Signal. 2011 May;23(5):948-9.

PMID:
19799997
5.

High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients.

Huttunen R, Syrjänen J, Aittoniemi J, Oja SS, Raitala A, Laine J, Pertovaara M, Vuento R, Huhtala H, Hurme M.

Shock. 2010 Feb;33(2):149-54. doi: 10.1097/SHK.0b013e3181ad3195.

PMID:
19487973
6.

Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.

Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR.

J Am Coll Surg. 2009 May;208(5):781-7; discussion 787-9. doi: 10.1016/j.jamcollsurg.2008.12.018.

7.

The human indoleamine 2,3-dioxygenase gene and related human genes.

Murray MF.

Curr Drug Metab. 2007 Apr;8(3):197-200. Review.

PMID:
17430106
8.

Expression Pattern and Clinicopathological Relevance of the Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase Protein in Colorectal Cancer.

Chen IC, Lee KH, Hsu YH, Wang WR, Chen CM, Cheng YW.

Dis Markers. 2016;2016:8169724. doi: 10.1155/2016/8169724. Epub 2016 Aug 8.

9.

Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients.

Hascitha J, Priya R, Jayavelu S, Dhandapani H, Selvaluxmy G, Sunder Singh S, Rajkumar T.

Clin Biochem. 2016 Aug;49(12):919-24. doi: 10.1016/j.clinbiochem.2016.04.008. Epub 2016 Apr 20.

PMID:
27106797
10.

IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.

Lee A, Kanuri N, Zhang Y, Sayuk GS, Li E, Ciorba MA.

PLoS One. 2014 Dec 26;9(12):e115848. doi: 10.1371/journal.pone.0115848. eCollection 2014. Erratum in: PLoS One. 2015;10(7):e0133098.

11.

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2.

Lee YK, Lee HB, Shin DM, Kang MJ, Yi EC, Noh S, Lee J, Lee C, Min CK, Choi EY.

Exp Mol Med. 2014 Nov 14;46:e121. doi: 10.1038/emm.2014.69.

12.

Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1.

Pantouris G, Serys M, Yuasa HJ, Ball HJ, Mowat CG.

Amino Acids. 2014 Sep;46(9):2155-63. doi: 10.1007/s00726-014-1766-3. Epub 2014 May 30.

PMID:
24875753
13.

The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM.

J Immunol. 2014 Feb 1;192(3):1231-40. doi: 10.4049/jimmunol.1300720. Epub 2014 Jan 3.

14.

Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors.

Meininger D, Zalameda L, Liu Y, Stepan LP, Borges L, McCarter JD, Sutherland CL.

Biochim Biophys Acta. 2011 Dec;1814(12):1947-54. doi: 10.1016/j.bbapap.2011.07.023. Epub 2011 Jul 31.

PMID:
21835273
15.

Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells.

Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H.

J Virol. 2011 Jan;85(2):1048-57. doi: 10.1128/JVI.01998-10. Epub 2010 Nov 17.

16.

Serum levels and activity of indoleamine2,3-dioxygenase and tryptophanyl-tRNA synthetase and their association with disease severity in patients with chronic kidney disease.

Bao YS, Ji Y, Zhao SL, Ma LL, Xie RJ, Na SP.

Biomarkers. 2013 Aug;18(5):379-85. doi: 10.3109/1354750X.2013.790074. Epub 2013 May 7.

PMID:
23651343
17.

Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice.

Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, Hunt NH.

Gene. 2007 Jul 1;396(1):203-13. Epub 2007 Apr 18. Erratum in: Gene. 2010 Oct 1;465(1-2):66.

PMID:
17499941
18.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

19.

An atlas of genetic influences on human blood metabolites.

Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, Arnold M, Erte I, Forgetta V, Yang TP, Walter K, Menni C, Chen L, Vasquez L, Valdes AM, Hyde CL, Wang V, Ziemek D, Roberts P, Xi L, Grundberg E; Multiple Tissue Human Expression Resource (MuTHER) Consortium, Waldenberger M, Richards JB, Mohney RP, Milburn MV, John SL, Trimmer J, Theis FJ, Overington JP, Suhre K, Brosnan MJ, Gieger C, Kastenmüller G, Spector TD, Soranzo N.

Nat Genet. 2014 Jun;46(6):543-550. doi: 10.1038/ng.2982. Epub 2014 May 11.

20.

Architecture of the human interactome defines protein communities and disease networks.

Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, Colby G, Gebreab F, Gygi MP, Parzen H, Szpyt J, Tam S, Zarraga G, Pontano-Vaites L, Swarup S, White AE, Schweppe DK, Rad R, Erickson BK, Obar RA, Guruharsha KG, Li K, Artavanis-Tsakonas S, Gygi SP, Harper JW.

Nature. 2017 May 25;545(7655):505-509. doi: 10.1038/nature22366. Epub 2017 May 17.

Supplemental Content

Support Center